INTRODUCTION<\/span><\/strong><\/p>\n The term diabetes was introduced by Aretaeus of Cappadocia, an eminent physician of the Pneumatic School, who lived in Alexandria and Rome during the 2nd<\/sup> century AD. He was a humoralist and was inspired by the Hippocratic ideas. He used the Greek verb \u03b4\u03b9\u03b1\u03b2\u03b1\u00ed\u03bd\u03c9 (diabaino = pass through) to define the condition in which a large quantity of urine passes through (\u03b4\u03b9\u03b1\u03b2\u03b1\u00ed\u03bd\u03b5\u03b9 (diabainei) = passes through) the kidneys.1<\/sup> Diabetes was identified as polyuria following consumption of large amounts of drinking water, broadly accepted by all physicians as a symptom of renal dysfunction, and classified among diseases affecting the kidneys.<\/p>\n PRECURSORS OF DIABETIC RETINOPATHY<\/strong><\/span><\/p>\n Although diabetes was a well-known disease as from the 2nd<\/sup> century AD, no clinician attempted to link this endocrine disorder with eye-pathology before the middle of the 19th<\/sup> century. In 1846, the French ophthalmologist and Professor of Hygiene in Paris, Appolinaire Bouchardat (1806-1886), reported the development of visual loss in the absence of cataract in diabetics. This was partly reversible and in most cases improvement was associated with better control of diabetes.2<\/sup> A few years later, Fran\u00e7ois Tavignot made similar observations.3<\/sup> However, no histopathological specimens were examined and the implication of macular disease in diabetes remained tentative until the invention of the ophthalmoscope.<\/p>\n THE RECOGNITION OF DIABETIC MACULOPATHY<\/strong><\/span><\/p>\n Even though the first ophthalmoscope was introduced by Herman von Helmholtz in 1851, the newly invented instrument was still too complicated and the required training was too time-consuming to render examination of the ocular fundus an easy matter.4<\/sup> It was Eduard J\u00e4ger (1818-1884) who constructed an instrument integrating in one apparatus the principles of Helmholtz\u2019s, Ruete\u2019s and other ophthalmoscopes,5<\/sup> and, using this instrument, J\u00e4ger was the first to observe diabetic macular changes in 1855.6<\/sup> J\u00e4ger had inexhaustible patience and exemplary precision in ophthalmoscopy and, in illustrating his findings, meticulously incorporated the smallest details into his pictures. He used the newly developed direct ophthalmoscope in order to produce one of the first atlases containing 21 colour plates of fundus paintings, which were drawn after 20-40 clinical sessions per patient.7<\/sup> He described \u2018roundish\u2019 or oval, yellowish spots and full or partial thickness extravasations through the retina in the macular region of a diabetic patient.8<\/sup> His findings were controversial at the time and Albrecht von Graefe (1828-1870) claimed that there was no proof of a cause-effect relationship between diabetes and retinal complications.9<\/sup> Von Graefe\u2019s scepticism was adopted by many of his colleagues, with the exception of Louis Desmarres (1810-1882) in 1858.10 THE DISCOVERY OF PROLIFERATIVE DIABETIC RETINOPATHY<\/strong><\/span><\/p>\n In 1876, Wilhelm Manz (1833-1911) published his seminal paper on \u2018Retinitis proliferans\u2019 containing several drawings of fibrovascular degeneration of the optic disc and vitreoretinal adhesions in the retina.14<\/sup> Fourteen years later, in 1890, Julius Hirschberg (1843-1925) classified diabetic retinopathy into four types (retinitis centralis punctuate, haemorrhagic form, retinal infarction, and haemorrhagic glaucoma), thus describing the full natural history of diabetic retinopathy.15<\/sup> The descriptive term, diabetic retinitis, though erroneous since the disease is not of inflammatory origin, continued to be used for several years.<\/p>\n At the beginning of the 20th<\/sup> century there was still the unresolved debate as to whether macular changes were directly related to diabetes or whether they were caused by atherosclerosis and hypertension. Arthur James Ballantyne (1876-1954) of Glasgow suggested that diabetic retinopathy represents a unique form of vasculopathy and his work showed for the first time the role of capillary wall alterations in the development of diabetic retinopathy, as well as the presence of deep waxy exudates in the outer plexiform layer.16 THE EVOLUTION OF THERAPEUTIC MODALITIES FOR DIABETIC RETINOPATHY<\/span><\/strong><\/p>\n In 1921, Frederick Banting (1891-1941) and Charles Best (1899-1978) extracted insulin from the pancreas, an achievement which is considered as one of the most significant contributions to endocrinology.18<\/sup> Over subsequent decades, various types of injectable long-acting insulin preparations were introduced for the treatment of diabetes, and other chemical agents were synthesized for oral administration to lower blood sugar,19<\/sup> which, in conjunction with other measures, improved diabetes control and helped in the prevention of ocular complications.<\/p>\n The German ophthalmologist Gerhard Meyer-Schwickerath (1920-1992) began looking for a way to use light to purposely coagulate retinal tissue after seeing the effects of a solar eclipse on the retina of a student. In 1950, he reported treatment of retinal disorders with photocoagulation.20<\/sup> The clinical application of this invention for diabetic retinopathy was carried out in 1963 by Paul Wetzig and his colleagues.21<\/sup> Charles Campbell and Christian Zweng were the first to use the ruby laser in a clinical setting, but it was William Beetham and Lloyd Aiello who recognized the effectiveness of photocoagulation in diabetic neovascular retinopathy.8<\/sup> In 1979, the Diabetic Retinopathy Study Research Group proved that both xenon arc and argon laser panretinal photocoagulation (PRP) significantly decrease the possibility of severe visual loss.22<\/sup> It is noteworthy that the exact mechanism by which PRP works remains unknown. In 1995, the Early Treatment Diabetic Retinopathy Study Research Group (ETDRS) confirmed the results of Patz who had demonstrated in 1976 that argon laser photocoagulation decreases or stabilizes macular oedema.23,24 The prognosis of diabetic retinopathy used to be gloomy. Today it is broadly accepted that diabetic retinopathy is a microvascular complication of diabetes mellitus and a significant cause of new-onset blindness. Severe and moderate vision loss from diabetes is essentially preventable with early detection and treatment, careful long-term follow-up, and comprehensive care by a multidisciplinary team of healthcare professionals. Several multi-centered clinical trials during the last ten years, and especially the Diabetic Control and Complications Trial (DCCT),27<\/sup> have significantly contributed to the understanding of the natural history of diabetic retinopathy and have established that strict glycaemic control reduces both the risk of onset and the progression of diabetic retinopathy and other microvascular complications of diabetes. Thus, future treatments, as outgrowths of further understanding of the biochemical basis of the disease, will aim at curing or preventing retinal complications from diabetes.<\/p>\n REFERENCES<\/strong><\/span><\/p>\n 1.\u00a0\u00a0 \u00a0Adams F, 1856 The extant works of Aretaeus the Cappadocian. Sydenham Society, London. George Kalantzis, Michael Angelou, Effie Poulakou-Rebelakou<\/p>\n
\n<\/sup>
\nNo further evidence was presented until 1869, when Henry Noyes (1832-1900) published an article in the USA supporting the link between diabetes mellitus and maculopathy.11<\/sup> His observations were confirmed in 1872 by Edward Nettleship (1845-1913) in London, who expanded on this theme in his paper entitled \u2018On oedema or cystic disease of the retina\u2019 and presented the first histopathological proof of a cystoid degeneration of the macula in diabetic patients.12<\/sup> Five years later, Nettleship published another article with Sir Steven Mackenzie (1791-1868), which described in detail the abnormal retinal changes induced by diabetes.13
\n<\/sup><\/p>\n
\n<\/sup>
\nToday the retinal manifestations of diabetes are classified as Early Non-proliferative Diabetic Retinopathy, Advanced Non-proliferative Diabetic Retinopathy, and Proliferative Diabetic Retinopathy.17
\n<\/sup><\/p>\n
\n<\/sup>
\nAlthough medical treatment of diabetic retinopathy progressed during the 1950\u2019s and 60\u2019s, surgical treatment remained experimental through these two decades. In 1953, Poulsen observed that progression of proliferative diabetic retinopathy was decelerated in a woman who developed post-partum pituitary necrosis (Simmonds\u2019 disease). Empirical trials of pituitary ablation were attempted as treatment for severe retinopathy.25<\/sup> Hypophysectomy was effective in 30% of patients suffering from proliferative retinopathy, but because of the traumatic nature of the operation and the requirement of post-operative hormone replacement therapy, the procedure was replaced by laser treatment. Robert Macherer (1933-), who was the first to establish an experimental model of retinal detachment, is best known for his development of pars plana vitrectomy for the treatment of vitreous haemorrhages in proliferative diabetic retinopathy.26
\n<\/sup>
\nCONCLUSION<\/strong><\/span><\/p>\n
\n2.\u00a0\u00a0 \u00a0Bouchardat A, 1846 Nouveau m\u00e9moire sur la glycosurie. Ann de Th\u00e9rap Suppl P pp, 162-311.
\n3.\u00a0\u00a0 \u00a0Tavignot B, 1853 De l\u2019amblyopie symptomatique du diab\u00e8te. Gaz des H\u00f4p: 412-413
\n4.\u00a0\u00a0 \u00a0Helmholtz H, 1851 Beschreibung eines Augenspiegels zur Untersuchung der Netzhaut im Lebenden Auge. Berlin, Jeanrenaud.
\n5.\u00a0\u00a0 \u00a0Albert DM, Edwards DD, 1996 The history of Ophthalmology. Blackwell Science, Massachusetts, pp, 195-196.
\n6.\u00a0\u00a0 \u00a0Jaeger E, 1855-1856 Beitr\u00e4ge zur Pathologie des Auges. Wien; p, 33
\n7.\u00a0\u00a0 \u00a0Hirschberg J, 1992 The History of Ophthalmology, translated by Blodi FC. Bonn, Wayenborgh Publisher, p, 146.
\n8.\u00a0\u00a0 \u00a0Wolfensberger TJ, Hamilton PA, 2001 Diabetic retinopathy – An historical review. Semin Ophthalmol 16: 2-7.
\n9.\u00a0\u00a0 \u00a0Von Graefe A, 1858 Ueber die mit Diabetes mellitus vorkommenden Sehst\u00f6rungen. Dies Arch IV: 230-234.
\n10.\u00a0\u00a0 \u00a0Desmarres L, 1858 Trait\u00e9 th\u00e9orique et pratique des maladies des yeux, Paris, vol III: 521-526
\n11.\u00a0\u00a0 \u00a0Noyes HD, 1869 Retinitis in glycosuria. Trans Am Ophthalmol Soc 4: 71-75.
\n12.\u00a0\u00a0 \u00a0Nettleship E, 1872 On oedema or cystic disease of the retina. Roy Ophth Lond Hosp Rep VII: 343-351.
\n13.\u00a0\u00a0 \u00a0Mackenzie S, Nettleship E, 1877 A case of glycosuric retinitis. Roy Ophth Lond Hosp Rep 9: 134.
\n14.\u00a0\u00a0 \u00a0Manz W, 1876 Retinitis proliferans. Graefes Arch Clin Exp Ophthalmol 22: 229.
\n15.\u00a0\u00a0 \u00a0Hirschberg J, 1890 \u00dcber diabetische Netzhautentz\u00fcndung. Dtsch Med Wochenschr 13: 1181.
\n16.\u00a0\u00a0 \u00a0Ballantyne AJ, Loewenstein A, 1943 Exudates in diabetic retinopathy. Trans Ophthalmol Soc UK 63: 95.
\n17.\u00a0\u00a0 \u00a0Yanoff M, Duker JS, 2004 Diabetic retinopathy. On: Ophthalmology, Mosby, St. Louis: 877-886.
\n18.\u00a0\u00a0 \u00a0Banting FG, Best CH, 1922 The internal secretion of the pancreas. J Lab Clin Med 7: 251-266.
\n19.\u00a0\u00a0 \u00a0Lyons AS, Petrucelli RJ, 1987 Medicine: an illustrated history. Abradale Press, New York; pp, 596-597.
\n20.\u00a0\u00a0 \u00a0Meyer-Schwickerath G, Koagulation der Netzhaut mit Sonnenlicht, 1950 Berl Dtsch Ophthalmol Ges 55: 256-259.
\n21.\u00a0\u00a0 \u00a0Wetzig PC, Worlton JT, 1963 Treatment of diabetic retinopathy by light-coagulation: a preliminary study. Br J Ophthalmol 47: 539-541.
\n22.\u00a0\u00a0 \u00a0Diabetic Retinopathy Study Research Group 1979, Four risk factors for severe visual loss in diabetic retinopathy: the third report from the Diabetic Retinopathy Study. Arch Ophthalmol 97: 654-665.
\n23.\u00a0\u00a0 \u00a0Early Treatment Diabetic Retinopathy Study Research Group, 1995 Focal photocoagulation treatment of diabetic macular edema. Relationship of treatment effect to fluorescein angiographic and other retinal characteristics at baseline: ETDRS Report No. 19. Arch Ophthalmol 113: 1144-1155.
\n24.\u00a0\u00a0 \u00a0Patz A, Schatz H, Berkow J, et al, 1973 Macular edema: an overlooked complication of diabetic retinopathy. Trans Am Acad Ophthalmol Otolaryngol 77: 34-42.
\n25.\u00a0\u00a0 \u00a0Poulsen JE, 1953 Recovery from retinopathy in a case of diabetes with Simmonds\u2019 disease. Diabetes 2: 7.
\n26.\u00a0\u00a0 \u00a0Macherer R, Buettner H, Norton WE, Parel JM, 1971 Vitrectomy: a pars plana approach. Trans Am Acad Ophthalmol Otolaryngol 75: 813-820.
\n27.\u00a0\u00a0 \u00a0Fong DS, Aiello L, Gardner TW, et al, 2003 Diabetic retinopathy. Diabetes Care 26: 226-229.<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"